Annotation Detail for MED12
Basic Information
Top
Pathway ID | Pathway Name |
---|
| Gene Expression |
Pathway ID | Pathway Name |
---|
200106 | Regulation of Wnt-mediated beta catenin signaling and target gene transcription |
Pathway ID | Pathway Name |
---|
500652 | Generic Transcription Pathway |
Desease ID | Desease Name |
---|
2001 | Mental retardation |
2069 | Schizophrenia |
2124 | Autistic disorder |
2152 | Renal tubular acidosis |
Desease Name |
---|
PSYCH |
depressive disorder, major |
phobia |
schizophrenia |
major depression |
psychoses |
Desease Name |
---|
Opitz-Kaveggia syndrome |
Lujan-Fryns syndrome |
Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
D017638 |
Asbestos, Crocidolite |
Asbestos, Crocidolite affects the expression of MED12 mRNA | affects expression | 17331233
|
D005038 |
Ethylnitrosourea |
Ethylnitrosourea results in increased mutagenesis of MED12 gene | increases mutagenesis | 16344459
|
D008767 |
Methylmercury Compounds |
Methylmercury Compounds results in increased expression of MED12 mRNA | increases expression | 16966085
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000236 |
Adenoma |
|
Ethylnitrosourea |
3.94 | 6695378 |
MESH:D001927 |
Brain Diseases |
|
Ethylnitrosourea |
5.33 | 14991843 |
MESH:D001932 |
Brain Neoplasms |
|
Ethylnitrosourea |
4.74 | 18412241 15144691 16651633 16436596 16357521 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
Ethylnitrosourea |
4.01 | 16003739 |
MESH:D016543 |
Central Nervous System Neoplasms |
|
Ethylnitrosourea |
6.85 | 17160924 |
MESH:D003704 |
Dementia |
|
Methylmercury Compounds |
5.48 | 16140633 |
MESH:D004476 |
Ectodermal Dysplasia |
|
Ethylnitrosourea |
6.85 | 18357618 |
MESH:D005909 |
Glioblastoma |
|
Ethylnitrosourea |
4.10 | 16436596 |
MESH:D005910 |
Glioma |
|
Ethylnitrosourea |
3.63 | 16357521 16651633 18412241 |
MESH:D007680 |
Kidney Neoplasms |
|
Ethylnitrosourea |
4.32 | 17379185 |
OMIM:309520 |
LUJAN-FRYNS SYNDROME |
marker/mechanism |
|
| |
MESH:D055370 |
Lung Injury |
|
Asbestos, Crocidolite |
4.67 | 17365036 |
MESH:D008175 |
Lung Neoplasms |
|
Ethylnitrosourea |
2.63 | 17703301 16019985 6695378 16271038 |
MESH:D008223 |
Lymphoma |
|
Ethylnitrosourea |
4.25 | 15790496 |
MESH:D016399 |
Lymphoma, T-Cell |
|
Ethylnitrosourea |
5.70 | 15375218 |
MESH:D058627 |
Macrocephaly |
marker/mechanism |
|
| 17334363 |
MESH:D008325 |
Mammary Neoplasms, Experimental |
|
Ethylnitrosourea |
3.77 | 10767621 18041768 10838139 |
MESH:D008569 |
Memory Disorders |
|
Methylmercury Compounds |
5.49 | 18436314 |
MESH:D008579 |
Meningioma |
|
Ethylnitrosourea |
6.85 | 17943659 |
MESH:D008654 |
Mesothelioma |
|
Asbestos, Crocidolite |
3.32 | 16966607 18303189 16166281 |
MESH:D009069 |
Movement Disorders |
|
Methylmercury Compounds |
5.85 | 18436314 |
MESH:D009123 |
Muscle Hypotonia |
marker/mechanism |
|
| 17334363 |
MESH:D009374 |
Neoplasms, Experimental |
|
Ethylnitrosourea |
5.05 | 16707424 |
MESH:D009442 |
Neurilemmoma |
|
Ethylnitrosourea |
6.16 | 16003739 17160924 16651423 |
MESH:D009837 |
Oligodendroglioma |
|
Ethylnitrosourea |
6.85 | 17160924 |
MESH:C537923 |
Opitz-Kaveggia syndrome |
marker/mechanism |
|
| 17334363 |
MESH:D010995 |
Pleural Diseases |
|
Asbestos, Crocidolite |
5.55 | 10923243 |
MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
Methylmercury Compounds |
5.72 | 18436314 |
MESH:D011658 |
Pulmonary Fibrosis |
|
Asbestos, Crocidolite |
3.16 | 17365031 17322281 17975199 15814490 |
MESH:D013953 |
Thymus Neoplasms |
|
Ethylnitrosourea |
5.90 | 15790496 |
Pathway ID |
Pathway Name |
---|
REACT:15380 |
Diabetes pathways |
REACT:71 |
Gene Expression |
REACT:27166 |
Transcriptional Regulation of Adipocyte Differentiation in 3T3-L1 Pre-adipocytes |
PharmGKB Accession:PA36645
Releated disease ID |
Related disease Name |
PA444929 | Mental Retardation |
PA446155 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
PA152241932 | Opitz-Kaveggia syndrome |